WAVE Life Sciences Ltd
NASDAQ:WVE
Net Margin
WAVE Life Sciences Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SG |
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
1B USD |
-90%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
834.7B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.1B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
211.3B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
189B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
163.6B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
210.3B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
116.9B EUR |
14%
|
WAVE Life Sciences Ltd
Glance View
WAVE Life Sciences Ltd. is a biotechnology company that sprawls across the intricate landscape of genetic medicine, focusing tirelessly on harnessing the therapeutic potential of stereochemistry in designing drugs. Founded with an innovative spirit, the company has carved out a niche by developing stereopure oligonucleotides, which are synthetically crafted RNA or DNA molecules tailored to enhance therapeutic efficacy and safety. The precision and clarity with which WAVE defines each aspect of its drug candidates separate them from many competitors in the gene therapy arena. With their proprietary platform, PRISM, WAVE leverages a deep understanding of genetic and molecular nuances to address rare genetic diseases. Their pipeline is reflective of this targeted approach, with clinical trials and research focusing on conditions like Huntington's disease, Duchenne Muscular Dystrophy, and other inherited disorders that have limited treatment options. The business model of WAVE revolves around both in-house development and strategic partnerships, driving revenue through research collaborations and potential milestone payments. By collaborating with larger pharmaceutical entities, WAVE amplifies its reach and resources, allowing it to tackle more complex challenges in genetic diseases. These partnerships are financially synergistic, enabling WAVE to continuously invest in its R&D efforts, which are pivotal for long-term growth and sustainability. The company’s focus on innovative medicines and the establishment of credible partnerships underscores its dual strategy of creating breakthrough treatments while maintaining a robust financial backbone, striving to transform the landscape of genetic therapies ethically and effectively.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on WAVE Life Sciences Ltd's most recent financial statements, the company has Net Margin of -89.6%.
You don't have any saved screeners yet